MDD to MDR Transition: A Practical Compliance Roadmap for 2026

The transition from the Medical Device Directive (MDD, 93/42/EEC) to the EU Medical Device Regulation (EU) 2017/745 (MDR) is no longer a future event — it is the present reality. Yet thousands of medical devices remain in various stages of incomplete transition. Manufacturers who have not yet achieved MDR certification face a shrinking window, constrained Notified Body capacity, and a regulatory landscape that has shifted multiple times since the MDR entered into force.

This guide is not a comparison of MDD and MDR requirements — for that, see our EU MDR vs MDD: Key Changes article. Instead, this is a practical, step-by-step roadmap for manufacturers who need to complete the transition. It covers current deadlines, legacy device provisions, documentation gap analysis, and concrete strategies for securing Notified Body engagement in a capacity-constrained environment.

1. Current State of the MDD to MDR Transition (2026 Status)

As of mid-2026, the transition landscape looks like this:

• The MDR has been fully applicable since 26 May 2021. No new MDD certificates have been issued since that date.
• Extended transition deadlines were introduced through Regulation (EU) 2023/607 (amending Article 120 of the MDR), granting additional time for certain legacy devices.
• EUDAMED remains partially operational. Key modules — particularly device registration and certificates — are live, but the full system is not yet mandatory for all regulatory processes.
• Notified Body capacity remains the single largest bottleneck. As of early 2026, fewer than 40 Notified Bodies are designated under the MDR, compared to approximately 80 that operated under MDD. The workload per body has increased dramatically due to stricter designation requirements and more complex conformity assessments.
• A significant number of legacy devices are still on the market under extended MDD certificates, and a meaningful percentage of manufacturers have not yet submitted their MDR applications.

The message is clear: the transition is not optional, the deadlines are firm, and the capacity to process applications is limited. Manufacturers who have not already begun active engagement with a Notified Body are at serious risk of market disruption.

2. Extended Transition Deadlines — Which Devices Get Extensions

The European Commission recognized that the original transition timeline was unrealistic given Notified Body capacity constraints. Regulation (EU) 2023/607 introduced staggered deadlines based on device risk classification:

Device Classification	Extended Deadline	Conditions
Class III and Class IIb implantable	26 May 2026	QMS certified, MDR application submitted to NB
Class IIb (non-implantable), Class IIa, Class Is/Im/Ir	31 December 2028	QMS certified, MDR application submitted to NB
Class I (up-classified under MDR)	31 December 2028	MDR application submitted to NB

Critical conditions for the extensions to apply:

1. The device must have had a valid MDD/AIMDD certificate that was still valid on 26 May 2021, or a valid Declaration of Conformity under MDD for Class I devices.
2. The manufacturer must have an MDR-compliant quality management system in place.
3. The manufacturer must have submitted a formal application to a Notified Body for MDR conformity assessment before the applicable deadline.
4. There must be no significant changes to the device design or intended purpose that would require a new conformity assessment under MDD.

Manufacturers who do not meet all four conditions cannot rely on the extended deadlines. Their devices must be withdrawn from the EU market when the relevant deadline passes.

3. Legacy Device Provisions Under Article 120

Article 120 of the MDR, as amended, governs the transitional provisions for legacy devices. Understanding these provisions in detail is essential for transition planning.

Devices with valid MDD certificates

Devices covered by MDD certificates issued before 26 May 2021 may continue to be placed on the market and put into service under the conditions described in Section 2 above. However, several important constraints apply:

• No significant changes: If the manufacturer makes a significant change to the device's design or intended purpose, the device can no longer benefit from the transitional provisions and must obtain MDR certification before being placed on the market.
• Post-market obligations apply immediately: Even devices benefiting from transitional provisions must comply with MDR post-market surveillance, vigilance, and market surveillance requirements from 26 May 2021 onwards. This is not optional.
• Sell-off provisions: Devices that were already in the supply chain (placed on the market) before the applicable deadline may continue to be made available until 26 May 2025 for Class III/IIb implantable, or 31 December 2028 for other classes.

Class I devices that were up-classified

Some devices that were Class I under MDD have been reclassified to higher risk classes under MDR (e.g., certain surgical reusable instruments now require Notified Body involvement). These devices benefit from the extended deadline of 31 December 2028, provided the manufacturer has filed an MDR application.

Key risk: the "no significant change" trap

Many manufacturers underestimate what constitutes a "significant change." Regulatory authorities have interpreted this broadly. Changes to materials, software algorithms, sterilization methods, or even labeling claims can be considered significant changes that invalidate the transitional provisions. Manufacturers should conduct a formal assessment of any changes made since their last MDD certification and document the rationale for why each change is or is not significant.

4. Notified Body Capacity Crisis

The Notified Body capacity gap is the defining challenge of this transition. Here is the current reality:

• Fewer than 40 MDR-designated Notified Bodies serve the entire European market, down from approximately 80 under MDD.
• Average review timelines for MDR conformity assessments range from 12 to 18 months after application acceptance, depending on device complexity and the specific Notified Body.
• Many Notified Bodies have closed their intake for new MDR applications for certain device categories, or have waiting lists extending 6-12 months before they will even accept an application.
• Cost increases of 30-60% compared to MDD certification are common, driven by the increased scope and depth of MDR conformity assessments.

Practical implications

1. Do not assume you can switch Notified Bodies easily. Transfer of files between bodies is complex and time-consuming. If your current NB is struggling, switching may actually delay your certification further.
2. Your application quality directly affects your timeline. Notified Bodies report that a large percentage of MDR applications are returned for deficiencies within the first few months. A well-prepared, complete application can save 6-12 months compared to an incomplete one.
3. Consider early engagement and pre-submission meetings. Many NBs offer pre-submission consultations. Investing in these can significantly reduce the risk of deficiency letters.

5. Technical Documentation Gap Analysis Checklist

The MDR requires technical documentation structured according to Annexes II and III, which are more prescriptive and detailed than the MDD Essential Requirements. Below is a gap analysis checklist for manufacturers transitioning from MDD documentation.

Device description and specification (Annex II, Section 1)

• Complete device description including all variants and accessories
• Intended purpose statement aligned with MDR terminology
• Reference to previous and similar device generations
• UDI assignment and labeling plan

Safety and performance requirements (Annex II, Section 2)

• GSPR checklist mapping each requirement to evidence (see Section 7 below)
• Identification of applicable harmonized standards and common specifications
• Risk-benefit analysis integrated into the documentation

Design and manufacturing information (Annex II, Section 3)

• Complete manufacturing process documentation
• Qualification and validation records for all critical processes
• Supplier controls and incoming inspection procedures
• Software lifecycle documentation (for devices with software, per IEC 62304)

General safety and performance requirements (Annex II, Section 4)

• Pre-clinical verification and validation data
• Biocompatibility evaluation per ISO 10993 (updated series)
• Electrical safety and electromagnetic compatibility testing
• Usability/human factors engineering file (IEC 62366-1)

Clinical evaluation (Annex II, Section 6)

• Clinical evaluation report compliant with MEDDEV 2.7/1 rev. 4
• PMCF plan with defined endpoints and methodology
• Summary of Safety and Clinical Performance (SSCP) for Class III and implantable devices
• Equivalence justification (if used) with contractual access documentation

Post-market surveillance (Annex III)

• PMS plan covering the device's entire lifecycle
• Periodic Safety Update Report (PSUR) template or completed document
• PMCF evaluation report
• Trend reporting procedures

6. Clinical Evaluation Upgrades Required

For most manufacturers, the clinical evaluation is the single most challenging component of the MDR transition. The upgrade requirements include:

Equivalence claims

Under MDD, many manufacturers relied on equivalence to competitor devices using published literature. Under MDR, this approach is severely restricted for Class III and implantable devices. Manufacturers must demonstrate:

• Clinical equivalence: Same clinical condition, same intended purpose, same patient population.
• Technical equivalence: Same materials, design, specifications, and manufacturing processes.
• Biological equivalence: Same tissue contact, same biocompatibility profile.
• Contractual access: A legally binding agreement granting access to the equivalent device's full technical documentation.

If equivalence cannot be established, manufacturers must generate their own clinical data — either through clinical investigations or through a sufficiently powered PMCF study.

PMCF requirements

Post-Market Clinical Follow-Up is now a mandatory, proactive process. PMCF plans must include:

• Defined clinical questions to be answered
• A methodology for data collection (e.g., patient registries, surveys, clinical studies)
• Defined milestones and reporting intervals
• Integration with the overall clinical evaluation update cycle

Summary of Safety and Clinical Performance (SSCP)

For Class III and implantable devices, the SSCP is a new MDR requirement. This document must be:

• Written in a format accessible to patients and healthcare professionals
• Uploaded to EUDAMED
• Updated at least annually alongside the clinical evaluation report

7. GSPR Mapping from Essential Requirements

One of the most time-consuming aspects of the transition is mapping from the MDD Essential Requirements (Annex I of MDD) to the MDR General Safety and Performance Requirements (Annex I of MDR).

The MDR GSPRs are organized into three chapters:

Chapter	GSPRs	Content
Chapter I	Requirements 1-9	General requirements (risk management, clinical evaluation, benefit-risk)
Chapter II	Requirements 10-22	Requirements regarding design and manufacture
Chapter III	Requirements 23	Requirements regarding information supplied with the device

Key differences from MDD Essential Requirements

• Risk management is now explicitly referenced: GSPR 1-3 require a documented risk management process aligned with ISO 14971, with specific emphasis on risk-benefit determination.
• Software-specific requirements: GSPR 17 includes dedicated provisions for software as a medical device (SaMD) and software incorporated into devices, requiring state-of-the-art development practices, cybersecurity considerations, and IT security measures.
• Usability engineering: GSPR 5 explicitly requires elimination or reduction of use errors through systematic usability engineering per IEC 62366-1.
• Chemical, physical, and biological properties: GSPR 10 has significantly expanded requirements regarding substances of concern (CMR, endocrine disruptors) requiring justification if present.

Mapping approach

1. Create a matrix listing each GSPR (1-23 plus sub-requirements).
2. For each GSPR, identify the corresponding MDD Essential Requirement.
3. Assess whether existing evidence satisfies the MDR requirement or whether gaps exist.
4. Prioritize gap closure by risk class and deadline.

8. Post-Market Surveillance System Upgrades

The MDR significantly expands post-market surveillance obligations compared to MDD. Manufacturers must upgrade their PMS systems in several areas:

PMS plan (Article 84)

Every device requires a PMS plan that is part of the quality management system. The plan must define how the manufacturer will:

• Collect and analyze data from post-market sources (complaint handling, vigilance, literature, registries)
• Identify trends in incidents, complaints, and performance issues
• Feed data back into the risk management process and clinical evaluation

Periodic Safety Update Report (PSUR)

• Class IIa, IIb, and III: PSUR must be prepared at least every two years (annually for Class III and implantable devices).
• Class I: A PMS report replaces the PSUR requirement, but must still be updated regularly.
• PSURs must be submitted to the Notified Body and, for Class III devices, uploaded to EUDAMED.

Trend reporting (Article 88)

Manufacturers must detect and report statistically significant increases in the frequency or severity of incidents or expected undesirable side effects. This requires:

• Defined statistical methodologies for trend detection
• Automated or semi-automated data aggregation from complaint, vigilance, and literature databases
• Documented thresholds and escalation procedures

Vigilance system upgrades

• Serious incident reporting timelines are tighter under MDR (2-15 days depending on severity).
• Field Safety Corrective Actions (FSCAs) must follow the new MDR format.
• Coordination with national competent authorities through the new electronic reporting systems.

9. Re-certification Strategy — Plan Your NB Engagement

Given the capacity constraints described above, your approach to Notified Body engagement can make or break your transition timeline. Here is a recommended strategy:

Phase 1: Internal readiness assessment (Months 1-3)

1. Conduct a complete gap analysis of your technical documentation against Annex II/III requirements.
2. Assess your clinical evaluation against MEDDEV 2.7/1 rev. 4 requirements.
3. Review your QMS for MDR alignment (particular attention to PMS, vigilance, and design control processes).
4. Classify or reclassify your devices under MDR classification rules (Annex VIII).

Phase 2: Notified Body engagement (Months 3-6)

1. Contact your current or prospective NB early. Do not wait until documentation is "perfect."
2. Request a pre-submission meeting or gap assessment service if available.
3. Submit a complete, high-quality application. Include a detailed device listing, GSPR checklist, and clinical evaluation summary.
4. Negotiate a realistic review timeline and understand the NB's deficiency management process.

Phase 3: Active review management (Months 6-18)

1. Respond to deficiency letters within the timeframe specified by the NB — typically 30-90 days.
2. Maintain open communication channels. Designate a single point of contact for NB interactions.
3. Track all open items in a structured matrix.
4. Prepare for audits (QMS audit, technical documentation review, unannounced audits).

Phase 4: Certification and transition (Months 18-24)

1. Obtain MDR certificate and update all labeling, IFUs, and declarations of conformity.
2. Register devices in EUDAMED.
3. Upload SSCP (for applicable devices).
4. Implement the PMS plan and begin PSUR cycle.

10. Timeline and Milestone Table

The following table provides a typical transition timeline for a mid-size manufacturer with a portfolio of Class IIa and IIb devices:

Milestone	Target Timeline	Key Activities	Dependencies
Gap analysis complete	Month 3	Technical documentation review, GSPR mapping, clinical evaluation assessment	Internal RA/QA resources
QMS updates complete	Month 6	PMS procedures, vigilance updates, design control alignment	Quality system team
Clinical evaluation updated	Month 9	CER update, PMCF plan, equivalence reassessment	Clinical affairs team, literature access
NB application submitted	Month 6-9	Complete application package, pre-submission meeting	NB capacity and availability
NB deficiencies addressed	Month 12-18	Response to questions, additional testing, documentation updates	NB review timeline
QMS audit completed	Month 15-20	On-site audit, corrective actions	NB scheduling
MDR certificate issued	Month 18-24	Certificate covers all devices in scope	All deficiencies closed
EUDAMED registration	Month 20-26	Device registration, UDI, SSCP upload	EUDAMED module availability
First PSUR submitted	Month 24-30	Data collection, trend analysis, clinical evaluation update	PMS data maturity

Important: These timelines assume a manufacturer that has already begun preparation. For manufacturers starting from scratch, add 6-12 months to each milestone.

11. How MedFlux Supports Your MDR Transition

Keeping track of evolving EU MDR requirements, guidances, and Notified Body communications is a continuous challenge. Regulatory intelligence is not a one-time exercise — it is an ongoing operational requirement.

MedFlux provides real-time monitoring of regulatory updates across the EU MDR landscape, including:

• Guidance document updates from the MDCG (Medical Device Coordination Group)
• Notified Body capacity and designation changes
• EUDAMED module releases and mandatory registration deadlines
• Harmonized standard updates relevant to your device portfolio
• Competent authority enforcement actions and market surveillance findings

Rather than manually tracking dozens of regulatory sources, MedFlux aggregates and structures this information so your regulatory affairs team can focus on compliance execution rather than information gathering.

Next Steps

The MDD to MDR transition is complex but manageable with proper planning. The key principles are:

1. Start now. Every month of delay narrows your options and increases risk.
2. Prioritize documentation quality over speed. A complete, well-structured application saves more time than a rushed one.
3. Engage your Notified Body early and proactively. Treat the relationship as a partnership, not a transaction.
4. Build your PMS system in parallel. Do not wait for certification to implement post-market surveillance — it is required during the transitional period.
5. Monitor regulatory changes continuously. The MDR implementation landscape continues to evolve, and staying current is not optional.

The manufacturers who navigate this transition successfully will not only maintain market access but will emerge with stronger regulatory systems, better clinical evidence, and more robust post-market processes — positioning them for long-term competitiveness in the European and global medical device market.